Provided by Tiger Fintech (Singapore) Pte. Ltd.

Perspective Therapeutics

1.85
-0.2400-11.48%
Post-market: 1.860.0096+0.52%19:37 EDT
Volume:731.32K
Turnover:1.40M
Market Cap:137.00M
PE:-1.50
High:2.09
Open:2.04
Low:1.82
Close:2.09
Loading ...

Optimistic Buy Rating for Perspective Therapeutics Amid Strategic Clinical Developments and Strong Financial Position

TIPRANKS
·
11 Apr

Perspective Therapeutics Doses First Patient in New Melanoma Trial Cohort With [212Pb]VMT01 Monotherapy

MT Newswires Live
·
11 Apr

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

GlobeNewswire
·
11 Apr

Truist Financial Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)

TIPRANKS
·
09 Apr

Perspective Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
07 Apr

Truist Securities Adjusts Price Target on Perspective Therapeutics to $10 From $21, Keeps Buy Rating

MT Newswires Live
·
07 Apr

U.S. RESEARCH ROUNDUP-Apple, Tesla, Walmart

Reuters
·
07 Apr

Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround

Zacks
·
02 Apr

Perspective Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
31 Mar

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

GlobeNewswire
·
31 Mar

Perspective Therapeutics (CATX) Receives a Hold from Bank of America Securities

TIPRANKS
·
28 Mar

Perspective Therapeutics Price Target Maintained With a $11.00/Share by Wedbush

Dow Jones
·
27 Mar

Analysts Offer Insights on Healthcare Companies: Allurion Technologies (ALUR), Perspective Therapeutics (CATX) and Nkarta (NKTX)

TIPRANKS
·
27 Mar

RBC Cuts Price Target on Perspective Therapeutics to $15 From $16, Keeps Outperform, Speculative Risk

MT Newswires Live
·
27 Mar

Perspective Therapeutics Reports 2024 Earnings and Clinical Progress

TIPRANKS
·
27 Mar

BRIEF-Perspective Therapeutics: Expect To Have Sufficient Funding Into Late 2026

Reuters
·
27 Mar

Perspective Therapeutics Inc: Expect to Have Sufficient Funding Into Late 2026

THOMSON REUTERS
·
27 Mar

Perspective Therapeutics FY 2024 GAAP EPS $(1.23) Misses $(0.87) Estimate, Sales $1.454M Beat $1.348M Estimate

Benzinga
·
27 Mar

Press Release: Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Dow Jones
·
27 Mar

Perspective Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Mar